Angiotech secures Edwards' vascular graft business in $14m cash deal
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals is to acquire Edwards Lifesciences' Lifespan line of ePTFE (expanded polytetrafluoroethylene) vascular grafts for a cash sum of $14m. The transaction is expected to close in the fourth quarter of 2005.